Glyset Mix Vial 100 IU/ml is a rapid-acting insulin analog formulated to improve glycemic control in patients with diabetes mellitus. Containing Insulin Aspart (rDNA) 100 IU/ml, it is designed to mimic the natural insulin response to meals, allowing for effective postprandial glucose management. Glyset Mix provides flexibility in diabetes therapy, whether used as part of a multiple daily injection regimen, continuous subcutaneous insulin infusion (CSII), or in combination with long-acting insulin for basal coverage.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Glyset Mix Vial 100 IU/ml is indicated for:

• Improvement of glycemic control in patients with type 1 or type 2 diabetes mellitus

• Meal-related glucose management as part of a basal-bolus insulin regimen

• Use in continuous subcutaneous insulin infusion (CSII) via external pumps for intensive insulin therapy

This insulin analog is particularly effective for controlling postprandial hyperglycemia due to its rapid onset and shorter duration compared to regular human insulin.

Therapeutic Class

• Rapid-Acting Insulin

Pharmacology

Insulin Aspart works by binding to insulin receptors on muscle and fat cells, enhancing glucose uptake into peripheral tissues while simultaneously suppressing hepatic glucose output. Its rapid absorption profile allows it to act quickly after administration, reducing postprandial blood glucose spikes.

Insulin Aspart has a faster onset and shorter duration of action than soluble human insulin, making it suitable for pre-meal administration or immediately after meals if needed.

Dosage and Administration

General dosing:

• Individualized according to patient needs, usually between 0.5–1.0 IU/kg/day in adults and children over 2 years

• Meal-related therapy: 50–70% of total daily insulin requirement is provided by Insulin Aspart, with the remainder from long-acting insulin

• Dose adjustment may be required for changes in diet, physical activity, or illness

Routes of administration:

• Subcutaneous injection: Abdomen, thigh, upper arm, or buttocks; inject immediately (5–10 minutes) before a meal

• Continuous Subcutaneous Insulin Infusion (CSII): Delivered via an external pump; approximately 50% as meal-related boluses and the remainder as basal infusion

• Intravenous use: For controlled hospital settings with close monitoring of glucose and potassium; stable in 0.9% sodium chloride infusion fluids at concentrations of 0.05–1.0 IU/ml

Patient Instructions:

• Use a pen device (e.g., ConviPen) or syringe as instructed

• Mix suspension uniformly by inverting the pen 8–10 times

• Remove air bubbles, set the correct dose, and inject carefully

• Avoid needle contamination to prevent infection

Drug Interactions

• Drugs reducing insulin requirements: Oral antidiabetics, ACE inhibitors, fibrates, fluoxetine, MAO inhibitors, salicylates, sulfonamide antibiotics

• Drugs increasing insulin requirements: Thiazides, glucocorticoids, thyroid hormones, beta-agonists, growth hormone, danazol

• Drugs that may potentiate or reduce insulin effect: Beta-blockers, clonidine, lithium, alcohol

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

• Hypoglycemia (most common)

• Allergic reactions

• Injection site reactions and lipodystrophy

• Pruritus and rash

Pregnancy and Lactation

• Pregnancy category B: Safe during pregnancy with careful monitoring

• Can be used during breastfeeding; may require dose adjustments

Precautions and Warnings

• Blood glucose monitoring is essential

• Adjust doses cautiously under medical supervision

• Educate patients on hypoglycemia recognition and treatment

• Mild hypoglycemia: treat with oral glucose or sugary foods

• Severe hypoglycemia: treat with glucagon (0.5–1 mg IM/SC) or IV glucose

Storage Conditions

• Store 2–8°C in a refrigerator

• Do not freeze

• Protect from light

• Keep out of reach of children.